Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Quinone reductase 2 inhibitors for use as neuroprotective agents

A nerve injury and alkyl technology, which can be used in nervous system diseases, medical preparations containing active ingredients, pharmaceutical formulas, etc., and can solve problems such as limited efficacy and side effects

Pending Publication Date: 2021-05-18
DUKE UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Although CQ and HQ are commonly used clinically as first-line therapy for autoimmune disorders, their efficacy is limited by severe side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quinone reductase 2 inhibitors for use as neuroprotective agents
  • Quinone reductase 2 inhibitors for use as neuroprotective agents
  • Quinone reductase 2 inhibitors for use as neuroprotective agents

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0213] Example 1: Development of non-lysosomal aminoquinoline inhibitors of QR2

[0214] Chloroquine and hydroxychloroquine are lysosomal drugs that preferentially accumulate in cellular lysosomes. Their structure is:

[0215]

[0216] For chloroquine, the pKa of the tertiary amine nitrogen is 10.32, and the pKa of the quinoline nitrogen is 7.29. At pH 4 to 5.5 in acidic lysosomes, almost 100% of chloroquine is thus doubly protonated, giving the molecule a 2 + The charge makes the molecule strongly hydrophilic, membrane impermeable, and thus trapped in acidic organelles.

[0217] This trapping phenomenon can be addressed quantitatively by measuring the octanol-water partition coefficient logD of the drug, which describes the relative partition properties of all forms of the compound at different pH. For a given pH, compounds with a positive logD are relatively lipophilic and more membrane permeable, while compounds with a negative logD are hydrophilic and less membrane p...

Embodiment 2

[0244] Embodiment 2: Synthesis and characterization of 7-chlorinated compounds

[0245]

[0246] A suspension of 4,7-dichloroquinoline (2.0 g, 10.2 mmol) in aqueous methylamine (40% 20 mL 260 mmol, 26 eq.) was placed in a microwave vessel at 90 °C (initial power set to 150 W ) heated for 2 hours. By TLC (2% in CH 2 Cl 2 Analysis of the reaction mixture showed complete consumption of starting material. with H 2 O (100 mL) diluted the reaction mixture and collected the insolubles in vacuo. filter cake with H 2 O washed and dried in vacuo to give the pure product as a white microcrystalline solid (1.8 g, 92%). 1 H NMR (DMSO- d 6 , 300 MHz) δ 8.40 (d, J = 5.1 Hz, 1H), 8.16 (d, J =9.0 Hz, 1H), 7.77 (s, 1H), 6.38 (d, J = 5.4 Hz, 1H), 2.86 ( d, J = 5.4 Hz,3H). ESIMS: m / z = 193 [(M+H) + ].

[0247]

[0248] General procedure for 7-substituted-4-(pyridin-3-yl)-methylaminoquinolines. A mixture of 7-substituted-4-chloroquinoline (5.1mmol), 3-aminomethylpyridine (0.70...

Embodiment 3

[0251] Example 3: Evidence for the protective effect of QR2 inhibition in cerebral infarction and the therapeutic effect of non-lysosomal QR2 inhibitors.

[0252] The neuroprotective efficacy of chloroquine (CQ) was demonstrated in a mouse model of transient middle cerebral artery (MCA) occlusion. Histological assessment at autopsy at 72 hours showed that a single intraperitoneal (i.p.) administration of CQ (25 mg / kg) 90 minutes after the onset of ischemia resulted in a 55% reduction in total stroke volume as measured by diffusion-weighted magnetic resonance imaging (DW- As measured by MRI, within 4 to 24 hours, there was a corresponding reduction in stroke development with improvements in neurological scores and motor function, as measured by Figures 3A-3C shown.

[0253] The non-lysosomal QR2-selective 4-aminoquinoline, 7-chloro-N-methylquinolin-4-amine (7C-4MAQ, Example compound F shown above) was also tested in the same model. Neuroprotective effect. In this animal mod...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein according to some embodiments is a method of treating acute neural injury in a subject in need thereof, comprising administering to the subject a compound of Formula I or Formula II. Also provided is a method of treating vascular dementia in a subject in need thereof, comprising administering to the subject a compound of Formula I or Formula II. Further provided is a method of treating CNS lupus in a subject in need thereof, comprising administering to the subject a compound of Formula I or Formula II.

Description

Background technique [0001] Aminoquinolines, based on chloroquine (CQ) and hydroxychloroquine (HQ), are quinone reductase 2 (QR2) inhibitors originally developed for the treatment of malaria, but have since been found to be therapeutically effective for other indications, including , in particular, autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Singer et al., "Update onimmunosuppressive therapy," Curr. Opin. Rheumatol. 1998, 10:169-173; Wallace, "The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a crude review," 1996, 5 Suppl 1:S59-64. For SLE and RA, aminoquinolines are the mainstay of first-line therapy and are often used in combination with other drugs. Aminoquinolines not only improve the signs and symptoms of SLE and RA, but also have beneficial effects on lipid metabolism and reduce the occurrence of thrombus. Similar benefits were observed in patients wi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4706A61K31/4709A61P25/00A61P25/28
CPCA61K31/4706A61K31/4709A61P25/00A61P25/28Y02A50/30
Inventor C·D·拉斯科拉J·K·菲茨帕特里克
Owner DUKE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com